NewAms­ter­dam notch­es an­oth­er win in res­ur­rec­tion of Am­gen car­dio drug

A Dutch biotech loaded with hun­dreds of mil­lions of dol­lars to res­ur­rect an old Am­gen drug has tout­ed an­oth­er mid-stage win for the cho­les­terol-low­er­ing as­set, and it will add an­oth­er Phase III tri­al to the line­up.

NewAms­ter­dam Phar­ma said the CETP in­hibitor, obice­trapib, cleared the ROSE2 tri­al, which test­ed obice­trapib on its own and as a com­bo with eze­tim­ibe, a non-statin LDL-low­er­ing drug. Some of the 119 pa­tients re­ceived place­bo for the 84-day treat­ment pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER